VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT00063713 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: VELCADE TM (bortezomib) for Injection

Sponsor

Millennium Pharmaceuticals, Inc.